Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma
  1. Home
  2. Publications
  3. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

Authors:
  • JTJoan Tymon-Rosario
    Joan Tymon-Rosario
  • EBElena Bonazzoli
    Elena Bonazzoli
  • SBStefania Bellone
    Stefania Bellone
  • NNNupur Nagarkatti
    Nupur Nagarkatti
  • LZLuca Zammataro
    Luca Zammataro
  • BZBurak Zeybek
    Burak Zeybek
  • JHJustin Harold
    Justin Harold
  • DMDennis Mauricio
    Dennis Mauricio
  • MCMitchell Clark
    Mitchell Clark
  • VAVaagn Andikyan
    Vaagn Andikyan
  • GHGloria Huang
    Gloria Huang

Publisher website
Google Scholar
  • 1 August 2021
    • journal article
    • Published by Elsevier in Gynecologic Oncology
    • Vol. 162, S186-S187
    • DOI:10.1016/s0090-8258(21)01001-5
Abstract
No abstract available
Keywords
  • HER2/NEU
  • ANTIBODY-DRUG CONJUGATE
  • PERTUZUMAB
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.